Increase in clonogenic tumour cells in bone marrow of patients with multiple myeloma treated with vincristine, doxorubicin, and methylprednisolone.
The relation between clonogenic myeloma cells, assayed in vitro, and clinical status was studied in 20 patients with multiple myeloma before and after VAMP therapy (vincristine, doxorubicin, and methylprednisolone). 14 patients showed an improvement in clinical status, as judged by a fall in myeloma protein and a decrease in plasmacytoid myeloma cell infiltration in the bone marrow. However, in 11 of these 14, there was an increase in the number of clonogenic myeloma cells. This suggests that the treatment changed the myeloma cell population in the residual bone marrow. To be effective, subsequent chemotherapy should be aimed at destroying this population of myeloma cells.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003114:Colony-Forming Units Assay; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009194:Myeloma Proteins / Q000032:analysis; D014410:Tumor Stem Cell Assay; D014750:Vincristine / Q000008:administration & dosage
D009194:Myeloma Proteins; D014750:Vincristine; D004317:Doxorubicin; D008775:Methylprednisolone